Biotech: Page
-
Getty Images
‘Really exciting times’: One biotech’s view of radiopharma’s boom
Backed by Bristol Myers Squibb, Ratio Therapeutics has a front row seat to the pharmaceutical industry’s pivot into the field of targeted radiation drugs.
By Michael Gibney • Sept. 17, 2024 -
Permission granted by QIAGEN
Sponsored by QIAGEN Digital InsightsEasy GxP compliance for NGS data – is it even possible?
NGS is changing the landscape for GxP compliance. How can you adapt?
Sept. 16, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Getty Images
Sponsored by SASGenerative AI can enhance pharmaceutical innovation – but are you ready for it?
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
By Susan Lenderts, Global Head of Life Sciences, SAS • Sept. 16, 2024 -
Getty Images
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
Roche has now beat Merck and Bristol Myers to market with its under-the-skin immunotherapy. Elsewhere, Sanofi bought into radiopharmaceuticals and Mene Pangalos joined Biogen's board.
By BioPharma Dive staff • Sept. 13, 2024 -
Spencer Platt via Getty Images
Three biotechs raise $700M in rare burst of IPO activity
Bicara Therapeutics, Zenas BioPharma and MBX Biosciences each priced upsized IPOs in the busiest week for biotech stock sales since February.
By Ben Fidler • Sept. 12, 2024 -
Jacob Bell/BioPharma Dive
Moderna to cut costs, trim pipeline in R&D revamp
As part of a broad restructuring, the company plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a spokesperson told BioPharma Dive.
By Ben Fidler • Sept. 12, 2024 -
Getty Images
F2G raises $100M to bring antifungal drug back to FDA
The funding, from AMR Action Fund and others, will help U.K.-based F2G complete late testing of a treatment that the FDA rejected one year ago.
By Delilah Alvarado • Sept. 12, 2024 -
Getty Images
GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug
The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity drug data and Lilly appointed a company veteran as its new CFO.
By BioPharma Dive staff • Sept. 11, 2024 -
Getty Images
Bain closes $3B biotech fund amid flurry of startup buyouts
The fund is Bain’s fourth and follows several recent acquisitions of some of its portfolio companies, among them Jnana Therapeutics and EyeBio.
By Delilah Alvarado • Sept. 10, 2024 -
Win McNamee via Getty Images
House backs bill restricting China role in US biotech
The Biosecure Act, which limits contracts with WuXi AppTec, WuXi Biologics and three other companies, still needs Senate support to advance.
By Jonathan Gardner • Sept. 10, 2024 -
Permission granted by Relay Therapeutics
Relay breast cancer drug shows potential in early trial
Results from a small study suggest Relay's drug could avoid some of the toxicity associated with existing PI3Ka inhibitors like Novartis' Piqray.
By Ned Pagliarulo • Sept. 9, 2024 -
shutterstock.com/Juan Gaertner
Early study data puts Terns among obesity drug contenders
A once-daily pill the biotech is developing helped some people with obesity lose more than 5% of their weight in a month, spurring a stock bump and plans to bring the drug into further testing.
By Jonathan Gardner • Sept. 9, 2024 -
Permission granted by Candid Therapeutics
Immune resetCandid, with $370M, sets out to prove bispecifics’ worth in autoimmune disease
The startup believes T cell engagers, rather than cell therapies, will prove the “right horse to bet on” in the race to develop new inflammatory disease treatments, its CEO said.
By Ben Fidler • Sept. 9, 2024 -
Stock.adobe.com
Sponsored by Quest DiagnosticsAccelerating Alzheimer’s therapy innovation: A new horizon in blood-based biomarkers
The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis and treatment.
By Dr. Michael K. Racke, Medical Director, Neurology, Quest Diagnostics • Sept. 9, 2024 -
Getty Images
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
OrsoBio is advancing several weight loss medicines. Elsewhere, Boehringer Ingelheim pushed forward with a geographic atrophy drug and Vaxcyte raised $1.3 billion.
By BioPharma Dive staff • Sept. 6, 2024 -
Getty Images
Lykos CEO to depart after FDA rejection, layoffs
The departure of Amy Emerson as CEO comes three weeks after the MDMA developer revealed plans to cut 75% of its staff.
By Ned Pagliarulo • Sept. 5, 2024 -
Getty Images
BioMarin, having retrenched, outlines plans for growth
The biotech is putting Voxzogo, its drug for skeletal disorders, at the center of plans to grow revenue the rest of this decade and beyond.
By Delilah Alvarado • Sept. 4, 2024 -
Getty Images
High-dose Spinraza meets study goal; Top Dyne executives exit
A new dose regimen of Biogen's spinal muscular atrophy drug appeared promising, while Denali Therapeutics and Regenxbio charted plans for drug approval applications.
By BioPharma Dive staff • Sept. 4, 2024 -
Getty Images
ArsenalBio raises $325M in one of the year’s largest biotech funding rounds
The financing comes amid a slowdown in venture investment for gene and cell therapy startups, and will support multiple solid tumor programs.
By Gwendolyn Wu • Sept. 4, 2024 -
Getty Images
Novo builds heart failure case for semaglutide; Ventyx CFO departs
A new analysis showed semaglutide reduced the risk of worsening heart failure. Elsewhere, the FDA OK’d a vaccine for mpox and a biotech planned layoffs.
By BioPharma Dive staff • Aug. 30, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin to lay off over 200 employees
The company has reshuffled its executive team, cut back spending and trimmed its drug pipeline this year, changes aimed at refocusing its resources.
By Delilah Alvarado • Aug. 29, 2024 -
Getty Images
Cell and gene therapy investment, once booming, is now in a slump
Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors.
By Gwendolyn Wu • Aug. 29, 2024 -
Sean Gallup via Getty Images
Bayer partners with RNA drugmaker to develop new cancer therapies
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with small molecule drugs.
By Delilah Alvarado • Aug. 28, 2024 -
Getty Images
RA Capital-backed startup raises $100M; UCB sells China business
New biotech Navigator is working on drugs for immune diseases. Meanwhile, UCB sold its neurology and allergy business in China, and J&J's Peter Fasolo will retire this year.
By BioPharma Dive staff • Aug. 27, 2024 -
Getty Images
Tome Biosciences to lay off over 100 employees
The buzzy startup, which had raised over $200 million in venture funding, is letting go of much of its workforce, according to a state regulatory notice.
By Delilah Alvarado • Aug. 26, 2024
Previous
